Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The PuMP Trial: MVR-C5252 in Recurrent High-Grade Glioma
NCT06126744Phase 1Recruiting
- Sponsor
- Duke University
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVR-C5252 in glioma and glioblastoma (GBM), sponsored by Duke University. Primary endpoints: Dose-Limiting Toxicity (Stage 1) at 28 days, Dose-Limiting Toxicity (Stage 2) at 56 days and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
MVR-C5252
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT06126744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126744.